M. Alexander Otto began his reporting career early in 1999 covering the pharmaceutical industry for a national pharmacists' magazine and freelancing for the Washington Post and other newspapers. He then joined BNA, now part of Bloomberg News, covering health law and the protection of people and animals in medical research. Alex next worked for the McClatchy Company. Based on his work, Alex won a year-long Knight Science Journalism Fellowship to MIT in 2008-2009. He joined the company shortly thereafter. Alex has a newspaper journalism degree from Syracuse (N.Y.) University and a master's degree in medical science -- a physician assistant degree -- from George Washington University. Alex is based in Seattle.
News
Atezolizumab TNBC indication ‘in jeopardy’ because of phase 3 results
Negative results from the IMpassion131 trial may jeopardize the U.S. approval of atezolizumab in breast cancer.
News
AI improves diagnostic accuracy in cervical cancer
A computer model outperformed traditional radiology in identifying lymph node involvement in cervical cancer.
News
PEGPH20 strikeout raises doubts about stroma-targeting agents in pancreatic cancer
There was no improvement in progression-free or overall survival when pegvorhyaluronidase alfa was added to nab-paclitaxel and gemcitabine.
News
The fix is in: AIM bundles to combat maternal morbidity and mortality
Some states ahead, some behind in nationwide roll out.
News
Genetic differences by ancestry shouldn’t impact efficacy of prostate cancer therapies
There were no significant differences in clinically actionable DNA repair genes, microsatellite instability-high status, or tumor mutation burden...
News
Intraventricular methotrexate may improve survival for medulloblastoma subtypes
Patients with desmoplastic medulloblastoma or medulloblastoma with extensive nodularity had high survival rates after receiving systemic...
News
Early data support further study of ivosidenib in mIDH1 glioma
The median progression-free survival was longer in patients with nonenhancing, versus enhancing, IDH1-mutated glioma.
News
Breast density asymmetry might increase breast cancer risk
Researchers have observed a trend, but the work continues.
News
Real-world data support adjuvant immunotherapy for stage III melanoma
Immunotherapy after surgery for stage III melanoma conferred survival advantages in a real-world population.
News
Azacitidine plus enasidenib improves response, but not survival, in mIDH2 AML
Enasidenib with, or after, azacitidine remains a question.
Article
ID dermatology: Advancements, but new challenges, over 50 years
One of the biggest wins for ID dermatology over the last 5 decades has been herpes. It started with the approval of acyclovir in 1981.
News
Combo exhibits activity in metastatic mucosal melanoma
The overall response rate was 48.5%.